References

Neurological adverse events of immune checkpoint inhibitors and the development of paraneoplastic neurological syndromes

10.1016/s1474-4422(23)00369-1 · 2024 · External reference

10.1016/s1474-4422(23)00335-6

10.1016/s1474-4422(23)00335-6 · External reference

Clinical Course of Neurologic Adverse Events Associated With Immune Checkpoint Inhibitors: Focus on Chronic Toxicities

10.1212/nxi.0000000000200314 · 2024 · External reference

10.1002/ana.25708

10.1002/ana.25708 · External reference

10.1212/wnl.0000000000011795

10.1212/wnl.0000000000011795 · External reference

Immune checkpoint inhibitor-related neurotoxicity: Incidence and management. A systematic review and meta-analysis

10.1016/j.ctrv.2025.103011 · 2025 · External reference

Features of myositis and myasthenia gravis in patients treated with immune checkpoint inhibitors: a multicentric, retrospective cohort study

10.1016/j.lanepe.2024.101192 · 2025 · External reference

Neurological outcomes in immune checkpoint inhibitor-related neurotoxicity

10.1093/braincomms/fcad169 · 2023 · External reference

Anti-Hu Antibodies in Patients With Neurologic Side Effects of Immune Checkpoint Inhibitors

10.1212/nxi.0000000000200058 · 2023 · External reference

Diagnostic and prognostic biomarkers in immune checkpoint inhibitor-related encephalitis: a retrospective cohort study

10.1016/j.lanepe.2024.101011 · 2024 · External reference

Neurological complications induced by immune checkpoint inhibitors: a comprehensive descriptive case-series unravelling high risk of long-term sequelae

10.1093/braincomms/fcab220 · 2021 · External reference

Encephalitis Induced by Immune Checkpoint Inhibitors: A Systematic Review

10.1001/jamaneurol.2021.0249 · 2021 · External reference

Longitudinally Extensive Myelitis Associated With Immune Checkpoint Inhibitors

10.1212/nxi.0000000000000967 · 2021 · External reference

10.1038/s41571-022-00600-w

10.1038/s41571-022-00600-w · External reference

Society for Immunotherapy of Cancer (SITC) consensus definitions for immune checkpoint inhibitor-associated immune-related adverse events (irAEs) terminology

10.1136/jitc-2022-006398 · 2023 · External reference

Neurotoxicity and safety of the rechallenge of immune checkpoint inhibitors: a growing issue in neuro-oncology practice

10.1007/s10072-022-05920-4 · 2022 · External reference

Consensus disease definitions for neurologic immune-related adverse events of immune checkpoint inhibitors

10.1136/jitc-2021-002890 · 2021 · External reference

Updated Diagnostic Criteria for Paraneoplastic Neurologic Syndromes

10.1212/nxi.0000000000001014 · 2021 · External reference

Diagnostic yield of commercial immunodots to diagnose paraneoplastic neurologic syndromes

10.1212/nxi.0000000000000701 · 2020 · External reference

10.1002/ana.26776

10.1002/ana.26776 · External reference

Anti-Neuronal Nuclear Antibody 3 Autoimmunity Targets Dachshund Homolog 1

10.1002/ana.26320 · 2022 · External reference

Calculating and Comparing the Annualized Relapse Rate and Estimating the Confidence Interval in Relapsing Neurological Diseases

10.3389/fneur.2022.875456 · 2022 · External reference

Soluble biomarkers for immune checkpoint inhibitor-related encephalitis: A mini-review

10.1016/j.neurol.2024.08.007 · 2024 · External reference

Neurological adverse events of immune checkpoint blockade: from pathophysiology to treatment

10.1097/wco.0000000000001113 · 2022 · External reference

10.1136/jnnp-2025-335998

10.1136/jnnp-2025-335998 · External reference

10.1016/j.ccell.2022.04.004

10.1016/j.ccell.2022.04.004 · External reference

1040O Phase II trial of ipilimumab, nivolumab and tocilizumab for unresectable metastatic melanoma

10.1016/j.annonc.2021.08.1425 · 2021 · External reference

JAK inhibition enhances checkpoint blockade immunotherapy in patients with Hodgkin lymphoma

10.1126/science.ade8520 · 2024 · External reference

Immune signatures of checkpoint inhibitor-induced autoimmunity-A focus on neurotoxicity

10.1093/neuonc/noad198 · 2024 · External reference

Reintroduction of immune-checkpoint inhibitors after immune-related meningitis: a case series of melanoma patients

10.1136/jitc-2020-001034 · 2020 · External reference

Safety of immune checkpoint inhibitor rechallenge after severe immune-related adverse events: a retrospective analysis

10.3389/fonc.2024.1403658 · 2024 · External reference

Incidence and Outcome of Neurologic Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitors in Patients With Melanoma

10.1212/wnl.0000000000207632 · 2023 · External reference